Biotech | September 18, 2021
Excision receives U.S. FDA clearance for first-in-human CRISPR Phase I/II trail for HIV
Initiation of EBT-101 Phase 1/2 clinical trial expected later this year
Initiation of EBT-101 Phase 1/2 clinical trial expected later this year
BB will have access to 100 million doses of vaccines annually and commercialization rights of the SILS vaccine portfolio for global markets
Sandoz is committed to building on its leading generic and biosimilar oncology portfolio to further expand patient access while contributing to the sustainability of healthcare systems
Hetero’s drug is a biosimilar version of Roche’s Actemra/RoActemra and will be available at the end of this month
The powder is approved for the treatment of adjunct therapy in moderate to severe Covid-19 patients
The agreement is to develop, manufacture and commercialise biosimilars for the global market.
First and only therapy approved by the FDA for the treatment of pruritus associated with chronic kidney disease (CKD-aP) in adults undergoing hemodialysis
Shanghai Roche Pharmaceuticals and Shanghai KeChow Pharma, entered into a cooperation agreement to improve market access of Zelboraf in China.
The group, known as the HIV Obstruction by Programmed Epigenetics (HOPE) Collaboratory, will be led by researchers at Gladstone Institutes, Scripps Research Florida, and Weill Cornell Medicine. Their approach, which aims to both silence and permanently remove HIV from the body, takes advantage of knowledge about how other viruses have become naturally inactivated over time.
Fitterfly has launched an online Prediabetes risk test which is an evidence-based, clinically validated tool for assessing an individual's risk of Prediabetes
Subscribe To Our Newsletter & Stay Updated
